APUS

Apimeds Pharmaceuticals US, Inc.

$2.69

-0.37%

SectorHealthcareIndustryDrug Manufacturers - Specialty & GenericCountryUnited States

Overview AI Brief ChartChart & Performance Financials ExposureRevenue Exposure FilingsFilings & Red Flags ScoresScores & Valuation News Analysts InsidersInsiders & Short Interest Ownership

Apimeds Pharmaceuticals US, Inc. provides digital asset treasury solutions in bitcoin treasury infrastructure. The company was incorporated in 2020 and is based in Matawan, New Jersey. Apimeds Pharmaceuticals US, Inc. operates as a subsidiary of Inscobee., Inc.

Source: Yahoo Finance

Market Cap$4.1M

Dividend Yield0.00%

Beta1.03

AI summary

Price & performance

1M+97.7%

3M-47.0%

YTD-79.0%

1Y-81.0%

52-week range—

Beta1.03

Full chart and returns against a benchmark

Q-Score

39/ 100

Quality against peers; 50 is the peer median.

Growth—

Risk29

Performance37

Valuation61

Profitability42

Leverage43

Sentiment—

Every score and metric

News sentiment

Open News

Latest results · FY 2025

Revenue—

Net income-$6M

Net margin—

Historical fundamentals

Red flags in filings

4active red flags

Going-concern doubtMay 4, 2026

Material weakness in controlsMay 4, 2026

Late filing noticeMay 15, 2026

Filings, findings and the timeline

Valuation

APUSIndustryP/E—35.25P/S—2.74EV/EBITDA—16.35P/B0.042.46PEG—0.87

Dividend yield0.00%

Every valuation metric

No reported financials for this company yet: it has too few SEC filings to chart.

Latest Results

The latest fiscal year and quarter, each against the same period a year earlier, from SEC filings.

Metric	FY 2025	vs a year before	Q2 2026	vs a year before
Net Income	-$6M	—	-$20.2M	—

Q-Scores

OverallCombines the categories below, except Sentiment

Industry 5939

Risk

Industry 6829

Performance

Industry 5937

Valuation

Industry 4961

Profitability

Industry 4942

Leverage

Industry 4443

Key Metrics

Fundamentals: trailing twelve months to Jun 2026, from the latest 10-K and 10-Qs.

Market Beta (5-factor)

IM 0.76SM 0.781.18

Market Cap

4.1M

Dividend Yield

IM 0.00%SM 0.00%0.00%

Volume

IM 1MSM 741.7K3.8M

Industry Market Share

0.00%

Sector Market Share

0.00%

IM industry median · SM sector median: the typical company the value is compared with. The /100 is its score against those peers.

Comparable Companies

The companies closest in size in Drug Manufacturers - Specialty & Generic (filled from its sector when there are few), with the median and rank across all 82 in the industry.

Company	Market cap	P/S	P/B	FCF yield	Revenue growth	Op. margin	ROE	Debt/equity
APUSApimeds Pharmaceuticals US, Inc.	$4.1M	—	0.0	-328.4%	—	—	-54.6%	0.0
GELSGelteq Limited	$4.5M	41.6	0.4	-80.2%	—	—	-42.0%	0.3
RDHLRedHill Biopharma Ltd.	$3.3M	0.3	—	-246.3%	157.6%	-110.4%	—	—
YCBDcbdMD, Inc.	$5.2M	0.2	0.6	-46.7%	10.0%	-13.9%	-35.2%	0.0
SNOASonoma Pharmaceuticals, Inc.	$5.5M	0.2	0.8	-48.6%	47.0%	-6.4%	-34.3%	0.0
PRFXPRF Technologies Ltd.	$2.8M	164.0	0.3	-141.9%	—	—	-58.8%	0.0
SBFMSunshine Biopharma, Inc.	$2.2M	0.1	0.1	-247.7%	-2.7%	-16.6%	-21.2%	0.0
UPCUniverse Pharmaceuticals INC	$7.8M	0.0	0.0	—	-22.4%	-16.3%	—	0.0
AKANAkanda Corp.	$1.9M	2.3	0.6	-198.2%	8.4%	-443.8%	-67.5%	0.1
Industry median		1.9	1.7	0.1%	8.9%	-7.1%	-14.9%	0.0
APUS percentile		—	4th	1st	—	—	21st	20th